<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111739">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01649271</url>
  </required_header>
  <id_info>
    <org_study_id>1200.134</org_study_id>
    <secondary_id>2012-001753-10</secondary_id>
    <nct_id>NCT01649271</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.</brief_title>
  <official_title>Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. Once the MTD of Afatinib With 3 Weekly Trastuzumab Was Established the Safety of This Dose Will be Assessed Also in Combination With Weekly Trastuzumab.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the Maximum Tolerated Dose (MTD) of afatinib in
      combination with 3-weekly trastuzumab in HER2 overexpressing cancer and to assess the
      efficacy of afatinib given at the MTD dosage, with 3-weekly trastuzumab in HER2
      overexpressing metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Objective response according to RECIST criteria version 1.1.</measure>
    <time_frame>up to 40 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ia: Determination of Maximum Tolerated Dose (MTD) of afatinib in combination with 3 weekly trastuzumab based on the occurence of DLTs during first treatment course.</measure>
    <time_frame>up to 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Progression Free Survival (PFS). Phase Ib: Best Overall Response (Complete Response, Partial Response or stable disease).</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Clinical benefit: Objective Response and Stable disease according to RECIST criteria version 1.1.</measure>
    <time_frame>up to 40 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ia: Objective response according to the RECIST criteria version 1.1.</measure>
    <time_frame>up to 40 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ia: Best overall response according to the Recist criteria version 1.1.</measure>
    <time_frame>up to 40 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Best Overall Response (Complete Response, Partial Response or stable disease)</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Phase Ia, group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>afatinib escalating dose with 3-weekly trastuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ia, group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>afatinib at MTD dose with weekly trastuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>afatinib at MTD level with 3-weekly trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>3-weekly</description>
    <arm_group_label>Phase Ia, group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>at MTD level</description>
    <arm_group_label>Phase Ia, group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>3-weekly</description>
    <arm_group_label>Phase Ib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>weekly</description>
    <arm_group_label>Phase Ia, group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>at MTD level</description>
    <arm_group_label>Phase Ib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>escalating dose</description>
    <arm_group_label>Phase Ia, group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients aged 18 years and older

          2. Patients with cancers overexpressing HER2 by Immunohistochemistry test( IHC) 3+
             and/or IHC 2+ with positive gene amplification by FISH (confirmation on archived
             tissue needed)

          3. Written informed consent that is consistent with ICH-GCP guidelines.

          4. Patients must be eligible for treatment with trastuzumab.

          5. Patients must have adequate organ function (kidney, liver, bone marrow, cardiac)

          6. Eastern Cooperative Oncology Group (ECOG) = 0 or 1.

          7. Measurable disease according to RECIST 1.1 (Phase Ib).

        Exclusion criteria:

          1. Active brain metastases.

          2. Prior treatment with erbB family targeting therapies within the past four weeks
             before start of therapy or concomitantly with the trial other than trastuzumab and/or
             lapatinib.

          3. Patients having more than 2 lines of chemotherapy for the treatment of metastatic
             breast cancer (Phase Ib).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.134.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.134.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Herblain Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.134.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 28, 2016</lastchanged_date>
  <firstreceived_date>July 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
